PRF1 and hepatocellular carcinoma: Sorafenib treatment can reduce the percentage of CD56brightCD16−NK cells and increase the frequency of CD56dimCD16+NK cells and the expression of granzyme B and perforin in total NK cells and both subsets of cells, improving the overall survival in HCC patients.